COOPERATION AGREEMENTCooperation Agreement • June 25th, 2020 • Theravance Biopharma, Inc. • Pharmaceutical preparations • New York
This COOPERATION AGREEMENT (this “Agreement”) is entered into as of June 22, 2020, by and among Theravance BIOPHARMA, Inc. (the “Company”), GlaxoSmithKline plc (“GSK”) and GSK FINANCE (NO.3) PLC (the “Issuer”).
REGISTRATION RIGHTS AGREEMENT AMONG THERAVANCE BIOPHARMA, INC. GLAXOSMITHKLINE PLC GSK FINANCE (NO.3) PLCRegistration Rights Agreement • June 25th, 2020 • Theravance Biopharma, Inc. • Pharmaceutical preparations • New York
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of June 22, 2020, is by and among THERAVANCE BIOPHARMA, INC., a Cayman Islands exempted company (the “Company”), GLAXOSMITHKLINE PLC, a public limited company incorporated under the laws of England and Wales, with registered number 03888792 (“GSK”), and GSK FINANCE (NO.3) PLC, a public limited company incorporated under the laws of England and Wales, with registered number 12615561 (“GSK Issuer”).
WAIVER AND ASSIGNMENT OF REGISTRATION RIGHTS AND VOTING AGREEMENTWaiver and Assignment of Registration Rights and Voting Agreement • June 25th, 2020 • Theravance Biopharma, Inc. • Pharmaceutical preparations • Delaware
This WAIVER AND ASSIGNMENT OF REGISTRATION RIGHTS AND VOTING AGREEMENT (this “Agreement”) is made and entered into as of June 22, 2020, by and among GSK Finance (No.3) plc, a public limited company incorporated under the laws of England and Wales (“GSK Finance”), Glaxo Group Limited (“GGL”) and Theravance Biopharma, Inc., a Cayman Islands exempted company (the “Company” and with GSK Finance and GGL, each a “Party”).
